ANI Pharmaceuticals sees FY26 revenue $1.055B-$1.115B, consensus $955.04M.

Provides full year 2026 financial guidance, which includes: Total net revenues of $1.055B-$1.115B; Cortrophin Gel net revenues of $540M-$575M; Adjusted non-GAAP EBITDA of $275M-$290M; Rare Disease business to represent approximately 60% of total net revenues. Announces ~90-person expansion of Rare Disease organization to capture unique opportunity for Cortrophin Gel in acute gouty arthritis flares; expected to deploy in mid-2026.